Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.68 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329619 | 1.00 | CD44 (0.68) | CD44PNMTALDH1A1HPGDKDM4E | |
| SCHEMBL29771844 | 0.81 | CD44 (1.00) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL329571 | 0.81 | CD44 (1.00) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL3659651 | 0.81 | CD44 (0.72) | CD44PNMTMAOBPRCP | |
| SCHEMBL30156803 | 0.81 | CD44 (0.72) | CD44PNMTMAOBPRCP | |
| Tert-Butyl Formate SCHEMBL28294146 | 0.80 | CD44 (0.47) | CD44TDP1 | |
| Hydrochloric Acid SCHEMBL4506036 | 0.79 | CD44 (0.96) | CD44PNMTMAOBPARP1PRCP | |
| Hydrochloric Acid SCHEMBL4520528 | 0.79 | CD44 (0.96) | CD44PNMTMAOBPARP1PRCP | |
| Hydrochloric Acid SCHEMBL4516826 | 0.79 | CD44 (0.70) | CD44PNMTMAOBPRCP | |
| SCHEMBL11327051 | 0.78 | CD44 (0.62) | CD44PNMTMAOBPARP1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048260-C0 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4545524-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-04-30 | — | — | EP | disclosed |
| EP-4441031-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4272737-A3 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023246944-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-12-28 | — | — | WO | disclosed |
| EP-4272737-A2 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116660431-A | Metabolic substance of lenalidomide in urine and application thereof | 詹晓凯 | 2023-08-29 | — | — | CN | disclosed |
| EP-3784663-B1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | CELGENE CORP (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
| EP-4048260-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | Celgene Corporation (US) | 2022-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | CD44 4293/4885PNMT 2341/4885ALDH1A1 1103/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | CD44 3212/4885PNMT 1030/4885ALDH1A1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.